83 related articles for article (PubMed ID: 10910032)
1. The epidermal growth factor receptor is required to maintain the proliferative population in the basal compartment of epidermal tumors.
Hansen LA; Woodson RL; Holbus S; Strain K; Lo YC; Yuspa SH
Cancer Res; 2000 Jul; 60(13):3328-32. PubMed ID: 10910032
[TBL] [Abstract][Full Text] [Related]
2. Targeted disruption of the epidermal growth factor receptor impairs growth of squamous papillomas expressing the v-ras(Ha) oncogene but does not block in vitro keratinocyte responses to oncogenic ras.
Dlugosz AA; Hansen L; Cheng C; Alexander N; Denning MF; Threadgill DW; Magnuson T; Coffey RJ; Yuspa SH
Cancer Res; 1997 Aug; 57(15):3180-8. PubMed ID: 9242447
[TBL] [Abstract][Full Text] [Related]
3. Autocrine transforming growth factor alpha is dispensible for v-rasHa-induced epidermal neoplasia: potential involvement of alternate epidermal growth factor receptor ligands.
Dlugosz AA; Cheng C; Williams EK; Darwiche N; Dempsey PJ; Mann B; Dunn AR; Coffey RJ; Yuspa SH
Cancer Res; 1995 May; 55(9):1883-93. PubMed ID: 7728756
[TBL] [Abstract][Full Text] [Related]
4. Development of an in vitro model to study carcinogen-induced neoplastic progression of initiated mouse epidermal cells.
Morgan D; Welty D; Glick A; Greenhalgh D; Hennings H; Yuspa SH
Cancer Res; 1992 Jun; 52(11):3145-56. PubMed ID: 1375535
[TBL] [Abstract][Full Text] [Related]
5. A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis.
Casanova ML; Larcher F; Casanova B; Murillas R; Fernández-Aceñero MJ; Villanueva C; Martínez-Palacio J; Ullrich A; Conti CJ; Jorcano JL
Cancer Res; 2002 Jun; 62(12):3402-7. PubMed ID: 12067982
[TBL] [Abstract][Full Text] [Related]
6. p53 gene dosage modifies growth and malignant progression of keratinocytes expressing the v-rasHa oncogene.
Weinberg WC; Azzoli CG; Kadiwar N; Yuspa SH
Cancer Res; 1994 Nov; 54(21):5584-92. PubMed ID: 7923201
[TBL] [Abstract][Full Text] [Related]
7. Activator protein 1 transcription factors are fundamental to v-rasHa-induced changes in gene expression in neoplastic keratinocytes.
Rutberg SE; Adams TL; Glick A; Bonovich MT; Vinson C; Yuspa SH
Cancer Res; 2000 Nov; 60(22):6332-8. PubMed ID: 11103794
[TBL] [Abstract][Full Text] [Related]
8. Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development.
Kiguchi K; Bol D; Carbajal S; Beltrán L; Moats S; Chan K; Jorcano J; DiGiovanni J
Oncogene; 2000 Aug; 19(37):4243-54. PubMed ID: 10980598
[TBL] [Abstract][Full Text] [Related]
9. Targeted disruption of the epidermal growth factor receptor inhibits development of papillomas and carcinomas from human papillomavirus-immortalized keratinocytes.
Woodworth CD; Gaiotti D; Michael E; Hansen L; Nees M
Cancer Res; 2000 Aug; 60(16):4397-402. PubMed ID: 10969784
[TBL] [Abstract][Full Text] [Related]
10. Differences in the regulation of intracellular calcium in normal and neoplastic keratinocytes are not caused by ras gene mutations.
Kruszewski FH; Hennings H; Tucker RW; Yuspa SH
Cancer Res; 1991 Aug; 51(16):4206-12. PubMed ID: 1907882
[TBL] [Abstract][Full Text] [Related]
11. Smad7 but not Smad6 cooperates with oncogenic ras to cause malignant conversion in a mouse model for squamous cell carcinoma.
Liu X; Lee J; Cooley M; Bhogte E; Hartley S; Glick A
Cancer Res; 2003 Nov; 63(22):7760-8. PubMed ID: 14633701
[TBL] [Abstract][Full Text] [Related]
12. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis.
Tiano HF; Loftin CD; Akunda J; Lee CA; Spalding J; Sessoms A; Dunson DB; Rogan EG; Morham SG; Smart RC; Langenbach R
Cancer Res; 2002 Jun; 62(12):3395-401. PubMed ID: 12067981
[TBL] [Abstract][Full Text] [Related]
13. Lack of transforming growth factor-beta 1 expression in benign skin tumors of p53null mice is prognostic for a high risk of malignant conversion.
Cui W; Kemp CJ; Duffie E; Balmain A; Akhurst RJ
Cancer Res; 1994 Nov; 54(22):5831-6. PubMed ID: 7954410
[TBL] [Abstract][Full Text] [Related]
14. Dermal fibroblast-derived growth factors restore the ability of beta(1) integrin-deficient embryonal stem cells to differentiate into keratinocytes.
Bagutti C; Hutter C; Chiquet-Ehrismann R; Fässler R; Watt FM
Dev Biol; 2001 Mar; 231(2):321-33. PubMed ID: 11237462
[TBL] [Abstract][Full Text] [Related]
15. The epidermal growth factor receptor: from development to tumorigenesis.
Sibilia M; Kroismayr R; Lichtenberger BM; Natarajan A; Hecking M; Holcmann M
Differentiation; 2007 Nov; 75(9):770-87. PubMed ID: 17999740
[TBL] [Abstract][Full Text] [Related]
16. PTEN loss promotes rasHa-mediated papillomatogenesis via dual up-regulation of AKT activity and cell cycle deregulation but malignant conversion proceeds via PTEN-associated pathways.
Yao D; Alexander CL; Quinn JA; Porter MJ; Wu H; Greenhalgh DA
Cancer Res; 2006 Feb; 66(3):1302-12. PubMed ID: 16452183
[TBL] [Abstract][Full Text] [Related]
17. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma.
Thomas SM; Bhola NE; Zhang Q; Contrucci SC; Wentzel AL; Freilino ML; Gooding WE; Siegfried JM; Chan DC; Grandis JR
Cancer Res; 2006 Dec; 66(24):11831-9. PubMed ID: 17178880
[TBL] [Abstract][Full Text] [Related]
18. Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras.
Kim SH; Nakagawa H; Navaraj A; Naomoto Y; Klein-Szanto AJ; Rustgi AK; El-Deiry WS
Cancer Res; 2006 Nov; 66(21):10415-24. PubMed ID: 17079462
[TBL] [Abstract][Full Text] [Related]
19. Cooperation between v-fos and v-rasHA induces autonomous papillomas in transgenic epidermis but not malignant conversion.
Greenhalgh DA; Quintanilla MI; Orengo CC; Barber JL; Eckhardt JN; Rothnagel JA; Roop DR
Cancer Res; 1993 Nov; 53(21):5071-5. PubMed ID: 7693330
[TBL] [Abstract][Full Text] [Related]
20. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
